PCM
MRTX

Penserra Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Penserra Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-380
Closed -$63K – 1147
2020
Q3 		$63K Buy
+380
New +$52K ﹤0.01% 610

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Penserra Capital Management's MRTX Position: Q4 2020 in Review

Penserra Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2020, closing a stake of 380 shares — an estimated $63K sold.

Penserra Capital Management first reported a position in MRTX in Q3 2020 and held it in 1 quarter. The position peaked at $63K in Q3 2020. 284 funds tracked by Wall St. Rank hold MRTX as of Q4 2020.

  • Penserra Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Penserra Capital Management sold 380 Mirati Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $63K.
  • Penserra Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • Penserra Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $63K in Q3 2020.
  • 284 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.